Wixner Jonas, Sundström Torbjörn, Karling Pontus, Anan Intissar, Suhr Ole B
Departments of Public Health and Clinical Medicine, Umeå University, S-90187, Umeå, Sweden.
Radiation Sciences, Umeå University, S-90187, Umeå, Sweden.
BMC Gastroenterol. 2015 Apr 25;15:51. doi: 10.1186/s12876-015-0284-4.
Hereditary transthyretin amyloid (ATTR) amyloidosis is a rare but fatal autosomal dominant condition that is present all over the world. A liver transplantation has been shown to halt the progress of the disease in selected patients and is currently considered to be the standard treatment. Gastrointestinal manifestations are common in hereditary ATTR amyloidosis and are important for the patients' morbidity and mortality. The aim of this study was to evaluate the long-term outcome of gastric emptying, gastrointestinal symptoms and nutritional status after liver transplantation for the disease.
Swedish patients with hereditary ATTR amyloidosis transplanted between 1990 and 2012 were included. A standardized method for measuring gastric emptying with a Tc(99m)-labelled meal followed by scintigraphy was utilized. Validated questionnaires were used to assess gastrointestinal symptoms and the modified body mass index (mBMI), in which BMI is multiplied by s-albumin, was used to evaluate nutritional status. Non-parametrical statistical tests were used.
Gastric emptying rates and nutritional statuses were evaluated approximately eight months before and two and five years after liver transplantation, whereas gastrointestinal symptoms were assessed in median nine months before and two and nine years after transplantation. No significant change was found in gastric emptying (median half-time 137 vs. 132 vs. 125 min, p = 0.52) or nutritional status (median mBMI 975 vs. 991 vs. 973, p = 0.75) after transplantation. Gastrointestinal symptom scores, however, had increased significantly over time (median score 7 vs. 10 vs. 13, p < 0.01).
Gastric emptying and nutritional status were maintained after liver transplantation for hereditary ATTR amyloidosis, although gastrointestinal symptom scores had increased over time.
遗传性转甲状腺素蛋白淀粉样变(ATTR)淀粉样变性是一种罕见但致命的常染色体显性疾病,全球均有发生。肝移植已被证明可使部分患者的疾病进展停止,目前被视为标准治疗方法。胃肠道表现是遗传性ATTR淀粉样变性的常见症状,对患者的发病率和死亡率具有重要影响。本研究旨在评估肝移植治疗该疾病后胃排空、胃肠道症状及营养状况的长期转归。
纳入1990年至2012年间接受肝移植的瑞典遗传性ATTR淀粉样变性患者。采用标准化方法,通过口服99m锝标记餐食后进行闪烁扫描来测量胃排空。使用经过验证的问卷评估胃肠道症状,并采用改良体重指数(mBMI,即BMI乘以血清白蛋白)评估营养状况。采用非参数统计检验。
在肝移植前约8个月、移植后2年和5年评估胃排空率和营养状况,而胃肠道症状分别在移植前中位数9个月、移植后2年和9年进行评估。移植后胃排空(中位数排空半衰期分别为137分钟、132分钟和125分钟,p = 0.52)或营养状况(中位数mBMI分别为975、991和973,p = 0.75)无显著变化。然而,胃肠道症状评分随时间显著增加(中位数评分分别为7、10和13,p < 0.01)。
肝移植治疗遗传性ATTR淀粉样变性后,胃排空和营养状况得以维持,尽管胃肠道症状评分随时间有所增加。